Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFMW) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Sunshine Biopharma (SBFMW) over the last 9 years, with Q3 2025 value amounting to $649850.0.

  • Sunshine Biopharma's Change in Receivables rose 16584.19% to $649850.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 3463.56%. This contributed to the annual value of $2.3 million for FY2024, which is 29354.21% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Change in Receivables of $649850.0 as of Q3 2025, which was up 16584.19% from -$65711.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Change in Receivables ranged from a high of $1.8 million in Q2 2024 and a low of -$986986.0 during Q3 2024
  • Over the past 5 years, Sunshine Biopharma's median Change in Receivables value was $6669.0 (recorded in 2021), while the average stood at $212951.2.
  • As far as peak fluctuations go, Sunshine Biopharma's Change in Receivables skyrocketed by 316620000.0% in 2023, and later plummeted by 165867.79% in 2024.
  • Sunshine Biopharma's Change in Receivables (Quarter) stood at $6669.0 in 2021, then skyrocketed by 7881.14% to $532262.0 in 2022, then dropped by 10.63% to $475659.0 in 2023, then surged by 113.81% to $1.0 million in 2024, then crashed by 36.1% to $649850.0 in 2025.
  • Its Change in Receivables was $649850.0 in Q3 2025, compared to -$65711.0 in Q2 2025 and -$426673.0 in Q1 2025.